

# Adrenal insufficiency: identification and management

**Evidence review M: Non-pharmacological strategies to prevent adrenal crisis during periods of psychological stress**

*NICE guideline NG243*

*Evidence reviews underpinning recommendations 1.5.4 to 1.5.5 in the NICE guideline*

*August 2024*

*Final*

*This evidence review was developed by NICE*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2024. All rights reserved. Subject to [Notice of rights](#).

ISBN: 978-1-4731-6474-1

# Contents

<b>1. Non-pharmacological interventions for psychological stress .....</b>	<b>5</b>
1.1. Review question .....	5
1.1.1. Introduction .....	5
1.1.2. Summary of the protocol .....	5
1.1.3. Methods and process .....	6
1.1.4. Effectiveness evidence .....	7
1.1.5. Summary of studies included in the effectiveness evidence .....	7
1.1.6. Summary of the effectiveness evidence .....	7
1.1.7. Economic evidence .....	7
1.1.8. Economic model .....	7
1.1.9. Unit costs .....	7
1.2. The committee's discussion and interpretation of the evidence .....	8
1.2.1. The outcomes that matter most .....	8
1.2.2. The quality of the evidence .....	8
1.2.3. Benefits and harms .....	8
1.2.4. Cost effectiveness and resource use .....	9
1.2.5. Recommendations supported by this evidence review .....	9
<b>References .....</b>	<b>10</b>
<b>Appendices .....</b>	<b>11</b>
Appendix A Review protocols .....	11
Appendix B Literature search strategies .....	22
Appendix C Effectiveness evidence study selection .....	39
Appendix D Effectiveness evidence .....	40
Appendix E Forest plots .....	40
Appendix F GRADE .....	40
Appendix G Economic evidence study selection .....	41
Appendix H Economic evidence tables .....	42
Appendix I Health economic model .....	42
Appendix J Excluded studies .....	43

# 1. Non-pharmacological interventions for psychological stress

## 1.1. Review question

What is the clinical and cost effectiveness of non-pharmacological strategies to prevent adrenal crisis during periods of psychological stress?

### 1.1.1. Introduction

Psychological stress may be a factor in precipitating or exacerbating adrenal crisis. A self-reported questionnaire-based study (White et al EJE) reported 1% of incidence of adrenal crisis being related to psychological stress. It is unclear how often this occurs as it is seen very rarely in clinical practice, and when it does is associated with severe sudden stress such as a bereavement. There is considerable variation in people's experience of psychological stress and its contributing factors. Although some stress is a normal part of life for most people, people with adrenal insufficiency may benefit from reducing their risk of severe psychological stress and adjusting their medicines when these happen, to maintain their health and well-being. It is important to consider the impact of psychological stress as a triggering factor for adrenal crisis and to provide advice on non-pharmacological strategies including self-management strategies that may help reduce stress and avoid a crisis.

This review explores non-pharmacological strategies, such as patient support groups, talking therapies and advice to prevent adrenal crises during periods of psychological stress.

### 1.1.2. Summary of the protocol

For full details see the review protocol in Appendix A.

**Table 1: PICO characteristics of review question**

<b>Population</b>	<p>Inclusion: People with adrenal insufficiency (primary, secondary, or tertiary) who are diagnosed or presumed adrenal insufficiency including the following groups: Strata:</p> <ul style="list-style-type: none"><li>• Adults (aged <math>\geq 16</math> years).</li><li>• Children aged <math>\geq 5</math> up to 16 years.</li><li>• Children aged <math>&lt; 5</math>.</li></ul> <p>Exclusion: None specified.</p>
<b>Interventions</b>	<ul style="list-style-type: none"><li>• Strategies to avoid the psychological stress: for example:</li><li>• Adapting environments</li><li>• Patient support and advice</li><li>• Patient support groups</li><li>• Peer support groups</li><li>• Clinical Nurse Specialist or pharmacist or non-medical practitioners (support)</li><li>• Access to urgent advice</li><li>• Structured counselling</li><li>• Flags on electronic records (e.g., schools, ambulance registrations)</li><li>• Patient held alerts e.g., cards, bracelets, steroid card.</li><li>• Mental health professional support for example psychiatrist</li></ul>

	<ul style="list-style-type: none"> <li>• Self-management strategies to improve mental health such as exercise, meditation, yoga.</li> <li>• Cognitive behavioural therapy</li> </ul>
<b>Comparisons</b>	<ul style="list-style-type: none"> <li>• Compared to each other</li> <li>• no intervention</li> <li>• standard/usual care as defined by authors</li> </ul>
<b>Outcomes</b>	<p>All outcomes are considered equally important for decision making and therefore have all been rated as critical:</p> <ul style="list-style-type: none"> <li>• Mortality</li> <li>• Health-related quality of life, for example EQ-5D, SF-36</li> <li>• Incidence of adrenal crisis</li> <li>• Admission to hospital</li> <li>• Admission to ITU</li> <li>• Length of hospital stay.</li> <li>• Readmission to hospital</li> <li>• Psychological morbidities e.g., Incidence of stress or PTSD</li> <li>• Mental health admission</li> </ul> <p>Follow up: Medium 6 months to a year If evidence only available for less than 6 months this will be included and downgraded for indirectness</p>
<b>Study design</b>	<p>Systematic reviews of RCTs and RCTs will be considered for inclusion. Cross-over trials will also be considered for inclusion regardless of washout period.</p> <p>If insufficient RCT evidence is available, a search for non-randomised studies will be considered if they have conducted a multivariate analysis adjusting for at least 3-4 of the following key confounders:</p> <ul style="list-style-type: none"> <li>-Age</li> <li>-Sex</li> <li>-Weight / BMI</li> <li>-Smoking</li> <li>-Time to treatment</li> <li>-Doses (timing or actual dose)</li> <li>-comorbidities e.g., heart disease, diabetes, kidney disease</li> <li>-socioeconomic status</li> <li>-educational attainment</li> <li>-health literacy</li> <li>-digital literacy</li> <li>-existing mental health diagnosis</li> </ul> <p>Published NMAs and IPDs will be considered for inclusion.</p>

### 1.1.3. Methods and process

This evidence review was developed using the methods and process described in [Developing NICE guidelines: the manual](#). Methods specific to this review question are described in the review protocol in Appendix A and the methods document.

Declarations of interest were recorded according to [NICE's conflicts of interest policy](#).

#### **1.1.4. Effectiveness evidence**

##### **1.1.4.1. Included studies.**

A search was conducted for randomised controlled trials (RCTs) and observational studies comparing non-pharmacological interventions for the management of psychological stress in people with adrenal insufficiency.

No relevant RCTs or observational studies were identified.

See also the study selection flow chart in Appendix C, study evidence tables in Appendix D, forest plots in Appendix E and GRADE tables in Appendix F.

##### **1.1.4.2. Excluded studies.**

See the excluded studies list in Appendix J.

#### **1.1.5. Summary of studies included in the effectiveness evidence.**

No clinical studies were included.

#### **1.1.6. Summary of the effectiveness evidence**

No clinical studies were included.

#### **1.1.7. Economic evidence**

##### **1.1.7.1. Included studies.**

No health economic studies were included.

##### **1.1.7.2. Excluded studies.**

No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.

See also the health economic study selection flow chart in Appendix G.

#### **1.1.8. Economic model**

This area was not prioritised for new cost-effectiveness analysis.

#### **1.1.9. Unit costs**

Relevant unit costs are provided below to aid the consideration of cost-effectiveness.

**Table 2: Staff costs associated with non-pharmacological interventions.**

<b>Resource</b>	<b>Cost per hour</b>
<b>Nurse</b>	
Band 5	£43.78
Band 6	£53.87
Band 7	£64.27
<b>Pharmacist</b>	
Band 6	£54.71

Resource	Cost per hour
Band 7	£65.73
<b>Psychologist</b>	
Band 5	£52.72
Band 6	£63.74
Band 7	£73.03
Band 8a	£85.81
Band 8b	£101.47
<b>Psychiatrist</b>	
Speciality register (48-hour week)	£68.89
Speciality register (56-hour week)	£58.96
Associate specialist	£144.22
Consultant	£152.65

Source: PSSRU 2020/21<sup>1</sup> including qualification costs (and excluding individual productivity costs)

**Table 3: Other costs associated with non-pharmacological interventions**

Resource	Unit costs
Steroid emergency card (100 cards)	£2.65

Source: Society for Endocrinology,<sup>3</sup> cost excludes VAT

## 1.2. The committee's discussion and interpretation of the evidence

### 1.2.1. The outcomes that matter most

The committee considered all outcomes listed in the protocol to be critical and of equal importance in decision-making. These outcomes included mortality, Health-related quality of life, incidence of adrenal crisis, admission to hospital or ITU and psychological morbidities such as incidence of stress or PTSD.

### 1.2.2. The quality of the evidence

No evidence was identified for this review.

### 1.2.3. Benefits and harms

In the absence of any evidence, the committee wished to make consensus recommendations reflecting the best current practice. The aim of the recommendations is to highlight the significance of psychological and emotional stress as a triggering factor for adrenal crisis and to provide advice on non-pharmacological strategies to aid self-management of psychological stress and avoid an adrenal crisis.

The committee acknowledged the importance of condition-specific patient support groups and organisations in providing information and support particularly to newly diagnosed patients. Patient support groups and organisations can promote and signpost people to support services to help manage anxiety and stress, including increasing awareness of exploring adjustments that might be possible within the workplace or educational setting. The committee discussed, that newly diagnosed patients may not be aware or have the confidence to request support from organisations such as employers, schools, or universities to enable them to continue with everyday activities. The committee agreed it was important



for people to know how to seek support if needed. The committee noted advising people and directing them on how they might access self-management strategies, such as exercise, or meditation can often help people in alleviating stress

The committee noted that people with adrenal insufficiency and diagnosed or undiagnosed anxiety or depression may need to be referred or advised to self-refer to NHS talking therapies or mental health services and decided to cross-refer to the recommendations in the NICE guideline on managing anxiety and depression.

#### **1.2.4. Cost effectiveness and resource use**

No economic evaluations were identified for this review; therefore, unit costs were presented to aid the committee's consideration of cost-effectiveness. Unit costs were obtained for a range of healthcare professionals who may deliver non-pharmacological interventions listed in the protocol. In addition, the cost of Steroid Emergency Cards was also presented.

The committee made recommendations reflective of best practice that would be given in the form of information and advice, and in line with NICE guidelines on managing anxiety and depression. In instances where best practice is not currently implemented, these recommendations cover the provision of information which will likely only involve a couple of minutes of extra staff time on top of existing patient contact with healthcare professionals. The committee included a consider recommendation for referral or self-referral to NHS talking therapies or mental health services. These recommendations are in line with existing NICE guidelines for managing anxiety and depression, which will have considered cost-effectiveness and are considered current practice. Therefore, these recommendations are not expected to result in a significant resource impact.

#### **1.2.5. Recommendations supported by this evidence review.**

This evidence review supports recommendations 1.5.4 – 1.5.5.

## References

1. Jones K, Burns A. Unit costs of health and social care 2021. Canterbury. Personal Social Services Research Unit University of Kent, 2021. Available from: <https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-of-health-and-social-care-2021/>
2. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: <https://www.nice.org.uk/process/pmg20/chapter/introduction>
3. Simpson H. New NHS Steroid Emergency Card: Available to order. Endocrinologist. 2020; (137)

# Appendices

## Appendix A Review protocols

### A.1 Review protocol for non-pharmacological management during periods of psychological stress.

ID	Field	Content
1.	Review title	Non-Pharmacological management during periods of psychological stress
2.	Review question	What is the clinical and cost effectiveness of non-pharmacological strategies to prevent adrenal crisis during periods of psychological stress?
3.	Objective	To determine the most clinically effective non-pharmacological strategies to prevent adrenal crisis during periods of psychological stress in people with adrenal insufficiency.
4.	Searches	<p>The following databases (from inception) will be searched:</p> <ul style="list-style-type: none"> <li>• AMED</li> <li>• CINAHL</li> <li>• Cochrane Central Register of Controlled Trials (CENTRAL)</li> <li>• Cochrane Database of Systematic Reviews (CDSR)</li> <li>• Embase</li> <li>• Epistemonikos</li> <li>• MEDLINE</li> <li>• PsycINFO</li> </ul> <p>Searches will be restricted by:</p> <ul style="list-style-type: none"> <li>• English language studies</li> </ul>

		<ul style="list-style-type: none"> <li>• Human studies</li> </ul> <p>The searches may be re-run 6 weeks before the final committee meeting and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies will be published in the final review.</p> <p>Medline search strategy to be quality assured using the PRESS evidence-based checklist (see methods chapter for full details).</p>
5.	Condition or domain being studied	Adrenal insufficiency
6.	Population	<p>Inclusion:</p> <p>People with adrenal insufficiency (primary, secondary, or tertiary) who are diagnosed or presumed adrenal insufficiency including the following groups:</p> <p>Strata:</p> <ul style="list-style-type: none"> <li>• Adults (aged <math>\geq 16</math> years)</li> <li>• Children aged <math>\geq 5</math> up to 16 years.</li> <li>• Children aged <math>&lt; 5</math>.</li> </ul> <p>Exclusion:</p> <p>None specified</p>
7.	Intervention	<ul style="list-style-type: none"> <li>• Strategies to avoid the psychological stress: for example, adapting environments,</li> <li>• Patient support and advice</li> <li>• Patient support groups</li> <li>• Peer support groups</li> <li>• Clinical Nurse Specialist or pharmacist or non-medical practitioners (support</li> <li>• Access to urgent advice</li> <li>• Structured counselling</li> <li>• Flags on electronic records (e.g., schools, ambulance registrations)</li> </ul>

		<ul style="list-style-type: none"> <li>• Patient held alerts e.g cards, bracelets, steroid card.</li> <li>• Mental health professional support for example psychiatrist</li> <li>• Self-management strategies to improve mental health such as exercise, meditation, yoga.</li> <li>• Cognitive behavioural therapy</li> </ul>
8.	Comparator	<ul style="list-style-type: none"> <li>• Compared to each other</li> <li>• no intervention</li> <li>• standard/usual care as defined by authors</li> </ul>
9.	Types of study to be included	<p>Systematic reviews of RCTs and RCTs will be considered for inclusion.</p> <p>Cross-over trials will also be considered for inclusion regardless of washout period.</p> <p>If insufficient RCT evidence is available, a search for non-randomised studies will be considered if they have conducted a multivariate analysis adjusting for at least 3-4 of the following key confounders:</p> <ul style="list-style-type: none"> <li>- Age</li> <li>- Sex</li> <li>- Weight / BMI</li> <li>- Smoking</li> <li>- Time to treatment</li> <li>- Doses (timing or actual dose)</li> <li>- comorbidities e.g heart disease, diabetes, kidney disease</li> <li>- socioeconomic status</li> <li>- educational attainment</li> <li>- health literacy</li> <li>- digital literacy</li> <li>- existing mental health diagnosis</li> </ul>

		Published NMAs and IPDs will be considered for inclusion.
10.	Other exclusion criteria	<p>Studies comparing glucocorticoids to mineralocorticoids or DHEAs to each other as each type of drug is given for different indications or symptoms and therefore a patient would not be prescribed one drug or the other.</p> <p>Non comparative cohort studies</p> <p>Before and after studies</p> <p>Comparisons of glucocorticoids or mineralocorticoids to placebo or no treatment</p> <p>Non-English language studies.</p> <p>Conference abstracts will be excluded because they are unlikely to contain enough information to assess whether the population matches the review question in terms of previous medication use, or enough detail on outcome definitions, or on the methodology to assess the risk of bias of the study.</p>
11.	Context	
12.	Primary outcomes (critical outcomes)	<p>All outcomes are considered equally important for decision making and therefore have all been rated as critical:</p> <p>Mortality</p> <p>Health-related quality of life, for example EQ-5D, SF-36</p> <p>Incidence of adrenal crisis</p> <p>Admission to hospital</p> <p>Admission to ITU</p> <p>Length of hospital stay.</p> <p>Readmission to hospital</p> <p>Psychological morbidities e.g., Incidence of stress or PTSD</p> <p>Mental health admission</p> <p><b>Follow up:</b> Medium 6 months to a year</p> <p>If evidence only available for less than 6 months this will be included and downgraded for indirectness</p>

13.	Data extraction (selection and coding)	<p>All references identified by the searches and from other sources will be uploaded into EPPI reviewer and de-duplicated.</p> <p>10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer.</p> <p>The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above.</p> <p>A standardised form will be used to extract data from studies (see <a href="#">Developing NICE guidelines: the manual</a> section 6.4).</p> <p>10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:</p> <ul style="list-style-type: none"> <li>• papers were included /excluded appropriately.</li> <li>• a sample of the data extractions</li> <li>• correct methods are used to synthesise data.</li> <li>• a sample of the risk of bias assessments</li> </ul> <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p> <p>Study investigators may be contacted for missing data where time and resources allow.</p>
14.	Risk of bias (quality) assessment	<p>Risk of bias will be assessed using the appropriate checklist as described in <a href="#">Developing NICE guidelines: the manual</a>.</p> <ul style="list-style-type: none"> <li>• Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS)</li> <li>• Randomised Controlled Trial: Cochrane RoB (2.0)</li> <li>• Nonrandomised study, including cohort studies: Cochrane ROBINS-I</li> </ul>
15.	Strategy for data synthesis	<p>Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5). Fixed-effects (Mantel-Haenszel) techniques will be used to calculate risk ratios for the binary outcomes where possible. Continuous outcomes will be analysed using an inverse variance method for pooling weighted mean differences.</p> <p>Heterogeneity between the studies in effect measures will be assessed using the <math>I^2</math> statistic and visually inspected. An <math>I^2</math> value greater than 50% will be considered indicative of substantial heterogeneity. Sensitivity analyses will be</p>

		<p>conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented pooled using random effects.</p> <p>GRADEpro will be used to assess the quality of evidence for each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome. Publication bias will be considered with the guideline committee, and if suspected will be tested for when there are more than 5 studies for that outcome.</p> <p>The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group <a href="http://www.gradeworkinggroup.org/">http://www.gradeworkinggroup.org/</a></p> <p>Where meta-analysis is not possible, data will be presented, and quality assessed individually per outcome.</p> <p>WinBUGS will be used for network meta-analysis, if possible, given the data identified.</p>	
16.	Analysis of sub-groups	<p>If it is appropriate to meta-analyse different types of exercise together or different types of support together and there is heterogeneity, we will investigate this by subgrouping into the different types of intervention. For example, exercise, may be sub-grouped into cardiovascular vs strength training or for support, subgrouping can be by clinical nurse practitioner vs consultant.</p>	
17.	Type and method of review	<input checked="" type="checkbox"/>	Intervention
		<input type="checkbox"/>	Diagnostic
		<input type="checkbox"/>	Prognostic
		<input type="checkbox"/>	Qualitative
		<input type="checkbox"/>	Epidemiologic
		<input type="checkbox"/>	Service Delivery
		<input type="checkbox"/>	Other (please specify)
18.	Language	English	
19.	Country	England	



20.	Anticipated or actual start date	June 2022		
21.	Anticipated completion date	April 2024		
22.	Stage of review at time of this submission	Review stage	Started	Completed
		Preliminary searches	<input checked="" type="checkbox"/>	<input type="checkbox"/>
		Piloting of the study selection process	<input type="checkbox"/>	<input type="checkbox"/>
		Formal screening of search results against eligibility criteria	<input type="checkbox"/>	<input type="checkbox"/>
		Data extraction	<input type="checkbox"/>	<input type="checkbox"/>
		Risk of bias (quality) assessment	<input type="checkbox"/>	<input type="checkbox"/>
		Data analysis	<input type="checkbox"/>	<input type="checkbox"/>
23.	Named contact	5a. Named contact Guideline Development Team NGC 5b Named contact e-mail Hypoadrenalism@nice.org.uk 5e Organisational affiliation of the review National Institute for Health and Care Excellence (NICE)		
24.	Review team members	From NICE: Sharon Swain [Guideline lead] Saoussen Ftouh [Senior systematic reviewer] Meena Tafazzoli [Technical Analyst] Lisa Miles [Technical Analyst] Alexandra Bannon [Health economist]		

		Stephen Deed [Information specialist]
25.	Funding sources/sponsor	Development of this systematic review is being funded by NICE.
26.	Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.
27.	Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of <a href="#">Developing NICE guidelines: the manual</a> . Members of the guideline committee are available on the NICE website: <a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10237">https://www.nice.org.uk/guidance/indevelopment/gid-ng10237</a> .
28.	Other registration details	-
29.	Reference/URL for published protocol	-
30.	Dissemination plans	NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as: <ul style="list-style-type: none"> <li>• notifying registered stakeholders of publication</li> <li>• publicising the guideline through NICE's newsletter and alerts</li> <li>• issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.</li> </ul>
31.	Keywords	-
32.	Details of existing review of same topic by same authors	-

33.	Current review status	<input type="checkbox"/>	Ongoing
		<input type="checkbox"/>	Completed but not published
		<input type="checkbox"/>	Completed and published
		<input type="checkbox"/>	Completed, published and being updated
		<input type="checkbox"/>	Discontinued
34.	Additional information	-	
35.	Details of final publication	<a href="http://www.nice.org.uk">www.nice.org.uk</a>	

## A.2 Health economic review protocol

**Table 4: Health economic review protocol**

Review question	All questions – health economic evidence
<b>Objectives</b>	To identify health economic studies relevant to any of the review questions.
<b>Search criteria</b>	<ul style="list-style-type: none"> <li>• Populations, interventions and comparators must be as specified in the clinical review protocol above.</li> <li>• Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</li> <li>• Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</li> <li>• Unpublished reports will not be considered unless submitted as part of a call for evidence.</li> <li>• Studies must be in English.</li> </ul>
<b>Search strategy</b>	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.
<b>Review strategy</b>	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2007, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).<sup>2</sup></p> <p><b>Inclusion and exclusion criteria</b></p> <ul style="list-style-type: none"> <li>• If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’, then it will be included in the guideline. A health economic evidence table will be completed, and it will be included in the health economic evidence profile.</li> <li>• If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’, then it will usually be excluded from the guideline. If it is excluded, then a health economic evidence table will not be completed, and it will not be included in the health economic evidence profile.</li> <li>• If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included.</li> </ul> <p><b>Where there is discretion</b></p> <p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.</p> <p>The health economist will be guided by the following hierarchies.  <i>Setting:</i></p>

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

*Health economic study type:*

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

*Year of analysis:*

- The more recent the study, the more applicable it will be.
- Studies published in 2007 or later but that depend on unit costs and resource data entirely or predominantly from before 2007 will be rated as 'Not applicable'.
- Studies published before 2007 be excluded before being assessed for applicability and methodological limitations.

*Quality and relevance of effectiveness data used in the health economic analysis:*

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

## Appendix B Literature search strategies

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.<sup>2</sup>

For more information, please see the Methodology review published as part of the accompanying documents for this guideline.

### B.1 Clinical search literature search strategy

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies as these concepts may not be indexed or described in the title or abstract and are therefore difficult to retrieve. Search filters were applied to the search where appropriate.

**Table 5: Database parameters, filters and limits applied**

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 6 January 2023	Randomised controlled trials Systematic review studies Observational studies  Exclusions (animal studies, letters, comments, editorials, case studies/reports)  English language
Embase (OVID)	1974 – 6 January 2023	Randomised controlled trials Systematic review studies Observational studies  Exclusions (animal studies, letters, comments, editorials, case studies/reports, conference abstracts)  English language
The Cochrane Library (Wiley)	Cochrane Database of Systematic Reviews to Issue 1 of 12, 6 January 2023  Cochrane Central Register of Controlled Trials to Issue 1 of 12, 6 January 2023	Exclusions (clinical trials, conference abstracts)
Epistemonikos (The Epistemonikos Foundation)	Inception to 6 January 2023	Systematic review  Exclusions (Cochrane reviews)
Current Nursing and Allied Health Literature (CINAHL) (EBSCO)	Inception to 6 January 2023	Human  Exclusions (Medline records)  English Language

Database	Dates searched	Search filter used
PsycINFO (OVID)	1806 to 6 January 2023	Human  Exclusions (letters, case reports, rodents)  English Language
Allied and Complementary Medicine (AMED) (OVID)	1985 to 6 January 2023	

### Medline (Ovid) search terms

1.	exp Adrenal Insufficiency/
2.	Adrenal Hyperplasia, Congenital/
3.	(addison* disease or addisonian*).ti,ab,kf.
4.	((adrenal* or adrenocort* or adreno cort*) adj3 (insufficien* or inadequa* or deficien* or suppress* or hypofunction* or disorder* or underactiv* or dysfunction* or abnormal* or problem* or crisis or crises or dysgenesis or destruction or destroy* or hyperplasia or hypoplasia or failure* or fails or failed or fatigue or inhibit* or damage* or disruption*).ti,ab,kf.
5.	((cortisol or aldosterone or adrenocorticotrop* or adreno corticotrop* or ACTH or corticotropi* releas* or corticotropi* releas* or corticoliberin or CRH) adj3 (insufficien* or inadequa* or deficien* or suppress* or reduc* or decreas* or descend* or diminish* or lack* or less or lessen* or low or lower* or limited)).ti,ab,kf.
6.	(hypoadrenal* or hypo adrenal* or hypoadrenocorticism or hypo adrenocorticism or adrenoleukodystrophy or adreno leukodystrophy or adrenomyeloneuropathy or adreno myeloneuropathy or hypoadosteronism or hypo aldosteronism).ti,ab,kf.
7.	((adrenogenital or adreno genital) adj (syndrome or disorder*).ti,ab,kf.
8.	((haemorrhag* or hemorrhag* or bleed*) adj3 adrenal*).ti,ab,kf.
9.	(Bronze Schilder* Disease or Melanodermic Leukodystrophy or Schilder-Addison* Complex or Siemerling-Creutzfeldt* Disease).ti,ab,kf.
10.	((Allgrove or 3A or TripleA or AAA) adj syndrome).ti,ab,kf.
11.	(CAH or X-ALD).ti,ab.
12.	(Waterhouse-Friderichsen* syndrome or antiphospholipid syndrome).ti,ab,kf.
13.	Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.ti,ab,kf.
14.	or/1-13
15.	letter/
16.	editorial/
17.	news/
18.	exp historical article/
19.	Anecdotes as Topic/
20.	comment/
21.	case reports/
22.	(letter or comment*).ti.
23.	or/15-22
24.	randomized controlled trial/ or random*.ti,ab.
25.	23 not 24
26.	animals/ not humans/
27.	exp Animals, Laboratory/
28.	exp Animal Experimentation/
29.	exp Models, Animal/

30.	exp Rodentia/
31.	(rat or rats or mouse or mice or rodent*).ti.
32.	or/25-31
33.	14 not 32
34.	limit 33 to English language
35.	Self-Help Groups/
36.	((self help or selfhelp or support*) adj3 (group* or network*)).ti,ab,kf.
37.	(peer adj2 (network* or support*)).ti,ab,kf.
38.	Self-Management/
39.	(self adj2 (manag* or care)).ti,ab,kf.
40.	(stress* adj3 (manag* or reduc* or adjust* or control* or adapt*)).ti,ab,kf.
41.	exp Cognitive Behavioral Therapy/
42.	(cognit* adj3 (behaviour* or behavior* or therap*)).ti,ab,kf.
43.	exp Exercise/ or Meditation/ or Yoga/ or exp Mindfulness/
44.	(exercis* or meditat* or yoga or mindfulness or mind aware*).ti,ab,kf.
45.	Counseling/ or Directive Counseling/
46.	(counselling or counseling or psychotherap* or psychiatr* or psycholog* or "talking therap*" or "structur* therap*").ti,ab,kf.
47.	Emergency Medical Tags/
48.	((patient or alert* or steroid or emergency or medical) adj3 (tag* or card* or bracelet* or wristband* or necklace* or keyring or ID jewellery)).ti,ab,kf.
49.	Electronic Health Records/
50.	((electronic or patient* or school* or ambulance) adj4 (record* or registration* or alert*)).ti,ab,kf.
51.	Patient Education as Topic/ or Patient Education Handout/
52.	((patient* or inpatient* or outpatient*) adj3 (inform* or advice or advis* or need* or requirement* or support* or access* or service* or educat* or learn* or teach* or train* or network*)).ti,ab,kf.
53.	((("nurse specialist*" or pharmacist* or dentist* or "healthcare professional*" or "health care professional*" or "health professional*" or psychiatrist* or psychologist* or psychotherapist* or counselor* or counsellor*) adj3 (inform* or advice or advis* or need* or requirement* or support* or access* or educat* or learn* or teach* or train*)).ti,ab,kf.
54.	or/35-53
55.	34 and 54
56.	randomized controlled trial.pt.
57.	controlled clinical trial.pt.
58.	randomi#ed.ab.
59.	placebo.ab.
60.	randomly.ab.
61.	clinical trials as topic.sh.
62.	trial.ti.
63.	cross-over studies/
64.	(crossover or "cross over").ti,ab.
65.	or/56-64
66.	Meta-Analysis/
67.	Meta-Analysis as Topic/
68.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
69.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.



70.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
71.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
72.	(search* adj4 literature).ab.
73.	(medline or pubmed or cochrane or embase or psychlit or psychlit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
74.	cochrane.jw.
75.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
76.	or/66-75
77.	Epidemiologic studies/
78.	Observational study/
79.	exp Cohort studies/
80.	(cohort adj (study or studies or analys* or data)).ti,ab.
81.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
82.	((longitudinal or retrospective or prospective) and (study or studies or review or analys* or cohort* or data)).ti,ab.
83.	Controlled Before-After Studies/
84.	Historically Controlled Study/
85.	Interrupted Time Series Analysis/
86.	(before adj2 after adj2 (study or studies or data)).ti,ab.
87.	exp case control study/
88.	case control*.ti,ab.
89.	Cross-sectional studies/
90.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
91.	or/77-90
92.	55 and (65 or 76 or 91)

### Embase (Ovid) search terms

1.	exp Adrenal cortex insufficiency/
2.	Congenital adrenal hyperplasia/
3.	(addison* disease or addisonian*).ti,ab,kf.
4.	((adrenal* or adrenocort* or adreno cort*) adj3 (insufficien* or inadequa* or deficien* or suppress* or hypofunction* or disorder* or underactiv* or dysfunction* or abnormal* or problem* or crisis or crises or dysgenesis or destruction or destroy* or hyperplasia or hypoplasia or failure* or fails or failed or fatigue or inhibit* or damage* or disruption*).ti,ab,kf.
5.	((cortisol or aldosterone or adrenocorticotrop* or adreno corticotrop* or ACTH or corticotropi* releas* or corticotropi* releas* or corticoliberin or CRH) adj3 (insufficien* or inadequa* or deficien* or suppress* or reduc* or decreas* or descend* or diminish* or lack* or less or lessen* or low or lower* or limited)).ti,ab,kf.
6.	(hypoadrenal* or hypo adrenal* or hypoadrenocorticism or hypo adrenocorticism or adrenoleukodystrophy or adreno leukodystrophy or adrenomyeloneuropathy or adreno myeloneuropathy or hypoaldosteronism or hypo aldosteronism).ti,ab,kf.
7.	((adrenogenital or adreno genital) adj (syndrome or disorder*).ti,ab,kf.
8.	((haemorrhag* or hemorrhag* or bleed*) adj3 adrenal*).ti,ab,kf.
9.	(Bronze Schilder* Disease or Melanodermic Leukodystrophy or Schilder-Addison* Complex or Siemerling-Creutzfeldt* Disease).ti,ab,kf.
10.	((Allgrove or 3A or TripleA or AAA) adj syndrome).ti,ab,kf.
11.	(CAH or X-ALD).ti,ab.

12.	(Waterhouse-Friderichsen* syndrome or antiphospholipid syndrome).ti,ab,kf.
13.	Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.ti,ab,kf.
14.	or/1-13
15.	letter.pt. or letter/
16.	note.pt.
17.	editorial.pt.
18.	case report/ or case study/
19.	(letter or comment*).ti.
20.	(conference abstract* or conference review or conference paper or conference proceeding).db,pt,su.
21.	or/15-20
22.	randomized controlled trial/ or random*.ti,ab.
23.	21 not 22
24.	animal/ not human/
25.	nonhuman/
26.	exp Animal Experiment/
27.	exp Experimental Animal/
28.	animal model/
29.	exp Rodent/
30.	(rat or rats or mouse or mice or rodent*).ti.
31.	or/23-30
32.	14 not 31
33.	limit 32 to english language
34.	self help/
35.	((self help or selfhelp or support*) adj3 (group* or network*)).ti,ab,kf.
36.	(peer adj2 (network* or support*)).ti,ab,kf.
37.	self care/
38.	(self adj2 (manag* or care)).ti,ab,kf.
39.	(stress* adj3 (manag* or reduc* or adjust* or control* or adapt*)).ti,ab,kf.
40.	exp cognitive behavioral therapy/
41.	(cognit* adj3 (behaviour* or behavior* or therap*)).ti,ab,kf.
42.	exp exercise/ or exp meditation/ or exp yoga/ or exp mindfulness/
43.	(exercis* or meditat* or yoga or mindfulness or mind aware*).ti,ab,kf.
44.	counseling/ or directive counseling/ or patient counseling/ or psychological counseling/
45.	(counselling or counseling or psychotherap* or psychiatr* or psycholog* or "talking therap*" or "structur* therap*").ti,ab,kf.
46.	emergency health service/
47.	((patient or alert* or steroid or emergency or medical) adj3 (tag* or card* or bracelet* or wristband* or necklace* or keyring or ID jewellery)).ti,ab,kf.
48.	electronic health record/
49.	((electronic or patient* or school* or ambulance) adj4 (record* or registration* or alert*)).ti,ab,kf.
50.	patient education/
51.	((patient* or inpatient* or outpatient*) adj3 (inform* or advice or advis* or need* or requirement* or support* or access* or service* or educat* or learn* or teach* or train* or network*)).ti,ab,kf.
52.	((("nurse specialist*" or pharmacist* or dentist* or "healthcare professional*" or "health care professional*" or "health professional*" or psychiatrist* or psychologist* or psychotherapist* or counselor* or counsellor*) adj3 (inform* or advice or advis* or

	need* or requirement* or support* or access* or educat* or learn* or teach* or train*)),ti,ab,kf.
53.	or/34-52
54.	33 and 53
55.	random*.ti,ab.
56.	factorial*.ti,ab.
57.	(crossover* or cross over*).ti,ab.
58.	((doubl* or singl*) adj blind*).ti,ab.
59.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
60.	crossover procedure/
61.	single blind procedure/
62.	randomized controlled trial/
63.	double blind procedure/
64.	or/55-63
65.	Systematic Review/
66.	Meta-Analysis/
67.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
68.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
69.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
70.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
71.	(search* adj4 literature).ab.
72.	(medline or pubmed or cochrane or embase or psychlit or psychlit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
73.	cochrane.jw.
74.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
75.	or/65-74
76.	Clinical study/
77.	Observational study/
78.	Family study/
79.	Longitudinal study/
80.	Retrospective study/
81.	Prospective study/
82.	Cohort analysis/
83.	Follow-up/
84.	cohort*.ti,ab.
85.	83 and 84
86.	(cohort adj (study or studies or analys* or data)).ti,ab.
87.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
88.	((longitudinal or retrospective or prospective) and (study or studies or review or analys* or cohort* or data)).ti,ab.
89.	(before adj2 after adj2 (study or studies or data)).ti,ab.
90.	exp case control study/
91.	case control*.ti,ab.
92.	cross-sectional study/
93.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
94.	or/76-82,85-93

95.	54 and (64 or 75 or 94)
-----	-------------------------

**Cochrane Library (Wiley) search terms**

#1.	MeSH descriptor: [Adrenal Insufficiency] explode all trees
#2.	MeSH descriptor: [Adrenal Hyperplasia, Congenital] this term only
#3.	((addison* NEXT disease) or addisonian*):ti,ab,kw
#4.	((adrenal* or adrenocort* or adreno-cort*) near/3 (insufficien* or inadequa* or deficien* or suppress* or hypofunction* or disorder* or underactiv* or dysfunction* or abnormal* or problem* or crisis or crises or dysgenesis or destruction or destroy* or hyperplasia or hypoplasia or failure* or fails or failed or fatigue or inhibit* or damage* or disruption*)):ti,ab,kw
#5.	((cortisol or aldosterone or adrenocorticotrop* or adreno-corticotrop* or ACTH or (corticotropi* NEXT releas*) or (corticotrophi* NEXT releas*) or corticoliberin or CRH) near/3 (insufficien* or inadequa* or deficien* or suppress* or reduc* or decreas* or descend* or diminish* or lack* or less or lessen* or low or lower* or limited)):ti,ab,kw
#6.	(hypoadrenal* or hypo-adrenal* or hypoadrenocorticism or "hypo adrenocorticism" or adrenoleukodystrophy or "adreno leukodystrophy" or adrenomyeloneuropathy or "adreno myeloneuropathy" or hypoaldosteronism or "hypo aldosteronism"):ti,ab,kw
#7.	((adrenogenital or "adreno genital") near/1 (syndrome or disorder*)):ti,ab,kw
#8.	((haemorrhag* or hemorrhag* or bleed*) near/3 adrenal*):ti,ab,kw
#9.	((Bronze NEXT Schilder*) or "Melanodermic Leukodystrophy" or (Schilder NEXT Addison*) or (Siemerling NEXT Creutzfeldt*)):ti,ab,kw
#10.	((Allgrove or 3A or TripleA or AAA) near/1 syndrome):ti,ab,kw
#11.	(CAH or "X-ALD"):ti,ab
#12.	((Waterhouse NEXT Friderichsen*) or "antiphospholipid syndrome"):ti,ab,kw
#13.	"Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy":ti,ab,kw
#14.	(or #1-#13)
#15.	conference:pt or (clinicaltrials or trialsearch):so
#16.	#14 not #15
#17.	MeSH descriptor: [Self-Help Groups] this term only
#18.	(("self help" or selfhelp or support*) near/3 (group* or network*)):ti,ab,kw
#19.	(peer near/2 (network* or support*)):ti,ab,kw
#20.	MeSH descriptor: [Self-Management] this term only
#21.	(self near/2 (manag* or care)):ti,ab,kw
#22.	(stress* near/3 (manag* or reduc* or near/ust* or control* or adapt*)):ti,ab,kw
#23.	MeSH descriptor: [Cognitive Behavioral Therapy] explode all trees
#24.	(cognit* near/3 (behaviour* or behavior* or therap*)):ti,ab,kw
#25.	MeSH descriptor: [Exercise] explode all trees
#26.	MeSH descriptor: [Meditation] this term only
#27.	MeSH descriptor: [Yoga] this term only
#28.	MeSH descriptor: [Mindfulness] explode all trees
#29.	(exercis* or meditat* or yoga or mindfulness or mind-awar*):ti,ab,kw
#30.	MeSH descriptor: [Counseling] this term only
#31.	MeSH descriptor: [Directive Counseling] this term only
#32.	(counselling or counseling or psychotherap* or psychiater* or psychologic* or talking-therap* or structured-therap*):ti,ab,kw
#33.	MeSH descriptor: [Emergency Medical Tags] this term only
#34.	((patient or alert* or steroid or emergency or medical) near/3 (tag* or card* or bracelet* or wristband* or necklace* or keyring or "ID jewellery")):ti,ab,kw
#35.	MeSH descriptor: [Electronic Health Records] this term only

#36.	((electronic or patient* or school* or ambulance) near/4 (record* or registration* or alert*)):ti,ab,kw
#37.	MeSH descriptor: [Patient Education as Topic] this term only
#38.	MeSH descriptor: [Patient Education Handout] this term only
#39.	((patient* or inpatient* or outpatient*) near/3 (inform* or advice or advis* or need* or requirement* or support* or access* or service* or educat* or learn* or teach* or train* or network*)):ti,ab,kw
#40.	((nurse-specialist* or pharmacist* or dentist* or ("health care" or healthcare or health) NEXT professional*) or psychiatrist* or psychologist* or psychotherapist* or counselor* or counsellor*) near/3 (inform* or advice or advis* or need* or requirement* or support* or access* or educat* or learn* or teach* or train*)):ti,ab,kw
#41.	(or #17-#40)
#42.	#16 and #41

### Epistemonikos search terms

1.	(title:(("adrenal insufficiency" OR "adrenal inadequacy" OR "adrenal deficiency" OR "adrenal suppression" OR "adrenal hypofunction" OR "adrenal disorder" OR "adrenal underactivity" OR "adrenal dysfunction" OR "adrenal crisis" OR "adrenal crises" OR "adrenal hypoplasia" OR "adrenal congenital hyperplasia" OR "addison disease" OR "addisons disease" OR "addison's disease" OR addisonian* OR hypoadrenal* OR "hypo adrenalism" OR hypoadrenocorticism OR "hypo adrenocorticism" OR adrenoleukodystrophy OR "adreno leukodystrophy" OR adrenomyeloneuropathy OR "adreno myeloneuropathy" OR hypoaldosteronism OR "hypo aldosteronism") OR abstract:(("adrenal insufficiency" OR "adrenal inadequacy" OR "adrenal deficiency" OR "adrenal suppression" OR "adrenal hypofunction" OR "adrenal disorder" OR "adrenal underactivity" OR "adrenal dysfunction" OR "adrenal crisis" OR "adrenal crises" OR "adrenal hypoplasia" OR "adrenal congenital hyperplasia" OR "addison disease" OR "addisons disease" OR "addison's disease" OR addisonian* OR hypoadrenal* OR "hypo adrenalism" OR hypoadrenocorticism OR "hypo adrenocorticism" OR adrenoleukodystrophy OR "adreno leukodystrophy" OR adrenomyeloneuropathy OR "adreno myeloneuropathy" OR hypoaldosteronism OR "hypo aldosteronism")) OR abstract:(("adrenal inadequacy" OR "adrenal deficiency" OR "adrenal suppression" OR "adrenal hypofunction" OR "adrenal disorder" OR "adrenal underactivity" OR "adrenal dysfunction" OR "adrenal crisis" OR "adrenal crises" OR "adrenal hypoplasia" OR "adrenal congenital hyperplasia" OR "addison disease" OR "addisons disease" OR "addison's disease" OR addisonian* OR hypoadrenal* OR "hypo adrenalism" OR hypoadrenocorticism OR "hypo adrenocorticism" OR adrenoleukodystrophy OR "adreno leukodystrophy" OR adrenomyeloneuropathy OR "adreno myeloneuropathy" OR hypoaldosteronism OR "hypo aldosteronism")))) AND (title:(("self help" OR selfhelp OR "self management" OR "self care" OR "stress managment" OR "cognitive behavioral therapy" OR "cognitive behavioural therapy" OR exercise OR meditation OR yoga OR mindfulness OR "mind awarenes" OR counselling OR counseling OR psychotherap* OR psychiatr* OR psycholog* OR "talking therap*" OR "structured therapy" OR "emergency medical tag" OR "emergency medical tags" OR "patient alert" OR "steroid card" OR "steroid cards" OR "emergency card" OR "emergency cards" OR bracelet* OR wristband* OR necklace* OR keyring OR "ID jewellery" OR "electronic record" OR "electronic records" OR "electronic health record" OR "electronic health records" OR "school record" OR "school records" OR "patient education" OR "patient support" OR "patient advice" OR "patient needs" OR "nurse specialist" OR pharmacist* OR dentist* OR "healthcare professional" OR "healthcare professionals" OR "health
----	--

	care professional" OR "health care professionals" OR "health professional" OR "health professionals" OR psychiatrist* OR psychologist* OR psychotherapist* OR counselor* OR counsellor*) OR abstract:("self help" OR selfhelp OR "self management" OR "self care" OR "stress management" OR "cognitive behavioral therapy" OR "cognitive behavioural therapy" OR exercise OR meditation OR yoga OR mindfulness OR "mind awarenes" OR counselling OR counseling OR psychotherap* OR psychiat* OR psychologic* OR "talking therap*" OR "structured therapy" OR "emergency medical tag" OR "emergency medical tags" OR "patient alert" OR "steroid card" OR "steroid cards" OR "emergency card" OR "emergency cards" OR bracelet* OR wristband* OR necklace* OR keyring OR "ID jewellery" OR "electronic record" OR "electronic records" OR "electronic health record" OR "electronic health records" OR "school record" OR "school records" OR "patient education" OR "patient support" OR "patient advice" OR "patient needs" OR "nurse specialist" OR pharmacist* OR dentist* OR "healthcare professional" OR "healthcare professionals" OR "health care professional" OR "health care professionals" OR "health professional" OR "health professionals" OR psychiatrist* OR psychologist* OR psychotherapist* OR counselor* OR counsellor*))
--	---

**CINAHL (EBSCO) search terms**

S1.	(MH "Adrenal Insufficiency+")
S2.	(MH "Adrenal Hyperplasia, Congenital")
S3.	TI ( (addison* disease or addisonian*) ) OR AB ( (addison* disease or addisonian*) )
S4.	TI ( ((adrenal* or adrenocort* or adreno cort*) AND (insufficien* or inadequa* or deficien* or suppress* or hypofunction* or disorder* or underactiv* or dysfunction* or abnormal* or problem* or crisis or crises or dysgenesis or destruction or destroy* or hyperplasia or hypoplasia or failure* or fails or failed or fatigue or inhibit* or damage* or disruption*)) ) OR AB ( ((adrenal* or adrenocort* or adreno cort*) AND (insufficien* or inadequa* or deficien* or suppress* or hypofunction* or disorder* or underactiv* or dysfunction* or abnormal* or problem* or crisis or crises or dysgenesis or destruction or destroy* or hyperplasia or hypoplasia or failure* or fails or failed or fatigue or inhibit* or damage* or disruption*)) )
S5.	TI ( ((cortisol or aldosterone or adrenocorticotrop* or adreno corticotrop* or ACTH or corticotropi* releas* or corticotrophi* releas* or corticoliberin or CRH) AND (insufficien* or inadequa* or deficien* or suppress* or reduc* or decreas* or descend* or diminish* or lack* or less or lessen* or low or lower* or limited)) ) OR AB ( ((cortisol or aldosterone or adrenocorticotrop* or adreno corticotrop* or ACTH or corticotropi* releas* or corticotrophi* releas* or corticoliberin or CRH) AND (insufficien* or inadequa* or deficien* or suppress* or reduc* or decreas* or descend* or diminish* or lack* or less or lessen* or low or lower* or limited)) )
S6.	TI ( (hypoadrenal* or hypo adrenal* or hypoadrenocorticism or hypo adrenocorticism or adrenoleukodystrophy or adreno leukodystrophy or adrenomyeloneuropathy or adreno myeloneuropathy or hypoaldosteronism or hypo aldosteronism) ) OR AB ( (hypoadrenal* or hypo adrenal* or hypoadrenocorticism or hypo adrenocorticism or adrenoleukodystrophy or adreno leukodystrophy or adrenomyeloneuropathy or adreno myeloneuropathy or hypoaldosteronism or hypo aldosteronism) )
S7.	TI ( ((adrenogenital or adreno genital) AND (syndrome or disorder*)) ) OR AB ( ((adrenogenital or adreno genital) AND (syndrome or disorder*)) )
S8.	TI ( ((haemorrhag* or hemorrhag* or bleed*) AND adrenal*) ) OR AB ( ((haemorrhag* or hemorrhag* or bleed*) AND adrenal*) )
S9.	TI ( (Bronze Schilder* Disease or Melanodermic Leukodystrophy or Schilder-Addison* Complex or Siemerling-Creutzfeldt* Disease) ) OR AB ( (Bronze Schilder* Disease or Melanodermic Leukodystrophy or Schilder-Addison* Complex or Siemerling-Creutzfeldt* Disease) )
S10.	TI ( ((Allgrove or 3A or TripleA or AAA) AND syndrome) ) OR AB ( ((Allgrove or 3A or TripleA or AAA) AND syndrome) )
S11.	TI ( (CAH or X-ALD) ) OR AB ( (CAH or X-ALD) )
S12.	TI ( (Waterhouse-Friderichsen* syndrome or antiphospholipid syndrome) ) OR AB ( (Waterhouse-Friderichsen* syndrome or antiphospholipid syndrome) )

S13.	TI Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy OR AB Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy
S14.	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
S15.	MH Support Groups
S16.	TI ( ((self help or selfhelp or support*) n3 (group* or network*)) ) OR AB ( ((self help or selfhelp or support*) n3 (group* or network*)) )
S17.	TI ( (peer n2 (network* or support*)) ) OR AB ( (peer n2 (network* or support*)) )
S18.	MH Self-Management
S19.	MH Self Care
S20.	TI ( (self n2 (manag* or care)) ) OR AB ( (self n2 (manag* or care)) )
S21.	TI ( (stress* n3 (manag* or reduc* or adjust* or control* or adapt*)) ) OR AB ( (stress* n3 (manag* or reduc* or adjust* or control* or adapt*)) )
S22.	MH Cognitive Therapy
S23.	TI ( (cognit* n3 (behaviour* or behavior* or therap*)) ) OR AB ( (cognit* n3 (behaviour* or behavior* or therap*)) )
S24.	(MH "Exercise")
S25.	MH Meditation
S26.	MH Yoga
S27.	MH Mindfulness
S28.	TI ( (exercis* or meditat* or yoga or mindfulness or mind awar*) ) OR AB ( (exercis* or meditat* or yoga or mindfulness or mind awar*) )
S29.	MH Counseling
S30.	TI ( (counselling or counseling or psychotherap* or psychiatr* or psychologic* or "talking therap*" or "structur* therap*") ) OR AB ( (counselling or counseling or psychotherap* or psychiatr* or psychologic* or "talking therap*" or "structur* therap*") )
S31.	(MH "Emergency Medical Tags")
S32.	TI ( ((patient or alert* or steroid or emergency or medical) n3 (tag* or card* or bracelet* or wristband* or necklace* or keyring or ID jewellery)) ) OR AB ( ((patient or alert* or steroid or emergency or medical) n3 (tag* or card* or bracelet* or wristband* or necklace* or keyring or ID jewellery)) )
S33.	MH Electronic Health Records
S34.	TI ( ((electronic or patient* or school* or ambulance) n4 (record* or registration* or alert*)) ) OR AB ( ((electronic or patient* or school* or ambulance) n4 (record* or registration* or alert*)) )
S35.	MH Patient Education
S36.	TI ( ((patient* or inpatient* or outpatient*) n3 (inform* or advice or advis* or need* or requirement* or support* or access* or service* or educat* or learn* or teach* or train* or network*)) ) OR AB ( ((patient* or inpatient* or outpatient*) n3 (inform* or advice or advis* or need* or requirement* or support* or access* or service* or educat* or learn* or teach* or train* or network*)) )
S37.	TI ( ( ("nurse specialist*" or pharmacist* or dentist* or "healthcare professional*" or "health care professional*" or "health professional*" or psychiatrist* or psychologist* or psychotherapist* or counselor* or counsellor*) n3 (inform* or advice or advis* or need* or requirement* or support* or access* or educat* or learn* or teach* or train*)) ) OR AB ( ( ("nurse specialist*" or pharmacist* or dentist* or "healthcare professional*" or "health care professional*" or "health professional*" or psychiatrist* or psychologist* or psychotherapist* or counselor* or counsellor*) n3 (inform* or advice or advis* or need* or requirement* or support* or access* or educat* or learn* or teach* or train*)) )
S38.	S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37

S39.	S14 AND S38
------	-------------

**PsycINFO (OVID) search terms**

1.	exp Adrenal Gland Disorders/
2.	(addison* disease or addisonian*).ti,ab,id.
3.	((adrenal* or adrenocort* or adreno cort*) adj3 (insufficien* or inadequa* or deficien* or suppress* or hypofunction* or disorder* or underactiv* or dysfunction* or abnormal* or problem* or crisis or crises or dysgenesis or destruction or destroy* or hyperplasia or hypoplasia or failure* or fails or failed or fatigue or inhibit* or damage* or disruption*).ti,ab,id.
4.	((cortisol or aldosterone or adrenocorticotrop* or adreno corticotrop* or ACTH or corticotropi* releas* or corticotropi* releas* or corticoliberin or CRH) adj3 (insufficien* or inadequa* or deficien* or suppress* or reduc* or decreas* or descend* or diminish* or lack* or less or lessen* or low or lower* or limited)).ti,ab,id.
5.	(hypoadrenal* or hypo adrenal* or hypoadrenocorticism or hypo adrenocorticism or adrenoleukodystrophy or adreno leukodystrophy or adrenomyeloneuropathy or adreno myeloneuropathy or hypoadosteronism or hypo aldosteronism).ti,ab,id.
6.	((adrenogenital or adreno genital) adj (syndrome or disorder*).ti,ab,id.
7.	((haemorrhag* or hemorrhag* or bleed*) adj3 adrenal*).ti,ab,id.
8.	(Bronze Schilder* Disease or Melanodermic Leukodystrophy or Schilder-Addison* Complex or Siemerling-Creutzfeldt* Disease).ti,ab,id.
9.	((Allgrove or 3A or TripleA or AAA) adj syndrome).ti,ab,id.
10.	(CAH or X-ALD).ti,ab.
11.	(Waterhouse-Friderichsen* syndrome or antiphospholipid syndrome).ti,ab,id.
12.	Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.ti,ab,id.
13.	or/1-12
14.	Letter/
15.	Case report/
16.	exp Rodents/
17.	or/14-16
18.	13 not 17
19.	limit 18 to (human and English language)
20.	support groups/
21.	((("self help" or selfhelp or support*) adj3 (group* or network*).ti,ab,id.
22.	(peer adj2 (network* or support*).ti,ab,id.
23.	self-management/ or self-help techniques/
24.	(self adj2 (manag* or care)).ti,ab,id.
25.	(stress* adj3 (manag* or reduc* or adjust* or control* or adapt*).ti,ab,id.
26.	exp cognitive behavior therapy/
27.	(cognit* adj3 (behaviour* or behavior* or therap*).ti,ab,id.
28.	exp exercise/ or meditation/ or yoga/ or mindfulness/
29.	(exercis* or meditat* or yoga or mindfulness or "mind aware").ti,ab,id.
30.	exp counseling/
31.	(counselling or counseling or psychotherap* or psychiatr* or psycholog* or "talking therap*" or "structur* therap*").ti,ab,id.
32.	((patient or alert* or steroid or emergency or medical) adj3 (tag* or card* or bracelet* or wristband* or necklace* or keyring or "ID jewellery").ti,ab,id.



33.	electronic health records/
34.	((electronic or patient* or school* or ambulance) adj4 (record* or registration* or alert*)).ti,ab,id.
35.	client education/
36.	((patient* or inpatient* or outpatient*) adj3 (inform* or advice or advis* or need* or requirement* or support* or access* or service* or educat* or learn* or teach* or train* or network*)).ti,ab,id.
37.	((("nurse specialist*" or pharmacist* or dentist* or "healthcare professional*" or "health care professional*" or "health professional*" or psychiatrist* or psychologist* or psychotherapist* or counselor* or counsellor*) adj3 (inform* or advice or advis* or need* or requirement* or support* or access* or educat* or learn* or teach* or train*)).ti,ab,id.
38.	or/20-37
39.	19 and 38

**AMED (OVID) search terms**

1.	Adrenal gland disease/
2.	(addison* disease or addisonian*).af.
3.	((adrenal* or adrenocort* or adreno cort*) adj3 (insufficien* or inadequa* or deficien* or suppress* or hypofunction* or disorder* or underactiv* or dysfunction* or abnormal* or problem* or crisis or crises or dysgenesis or destruction or destroy* or hyperplasia or hypoplasia or failure* or fails or failed or fatigue or inhibit* or damage* or disruption*)).af.
4.	((cortisol or aldosterone or adrenocorticotrop* or adreno corticotrop* or ACTH or corticotropi* releas* or corticotropi* releas* or corticoliberin or CRH) adj3 (insufficien* or inadequa* or deficien* or suppress* or reduc* or decreas* or descend* or diminish* or lack* or less or lessen* or low or lower* or limited)).af.
5.	(hypoadrenal* or hypo adrenal* or hypoadrenocorticism or hypo adrenocorticism or adrenoleukodystrophy or adreno leukodystrophy or adrenomyeloneuropathy or adreno myeloneuropathy or hypoadosteronism or hypo aldosteronism).af.
6.	((adrenogenital or adreno genital) adj (syndrome or disorder*)).af.
7.	((haemorrhag* or hemorrhag* or bleed*) adj3 adrenal*).af.
8.	(Bronze Schilder* Disease or Melanodermic Leukodystrophy or Schilder-Addison* Complex or Siemerling-Creutzfeldt* Disease).af.
9.	((Allgrove or 3A or TripleA or AAA) adj syndrome).af.
10.	(CAH or X-ALD).af.
11.	(Waterhouse-Friderichsen* syndrome or antiphospholipid syndrome).af.
12.	Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.af.
13.	or/1-12
14.	self help groups/
15.	((("self help" or selfhelp or support*) adj3 (group* or network*)).af.
16.	(peer adj2 (network* or support*)).af.
17.	self care/
18.	(self adj2 (manag* or care)).af.
19.	(stress* adj3 (manag* or reduc* or adjust* or control* or adapt*)).af.
20.	Cognitive therapy/
21.	(cognit* adj3 (behaviour* or behavior* or therap*)).af.
22.	exp exercise/ or meditation/ or yoga/

23.	(exercis* or meditat* or yoga or mindfulness or "mind awar*").af.
24.	counseling/
25.	(counselling or counseling or psychotherap* or psychiatr* or psycholog* or "talking therap*" or "structur* therap*").af.
26.	((patient or alert* or steroid or emergency or medical) adj3 (tag* or card* or bracelet* or wristband* or necklace* or keyring or "ID jewellery")).af.
27.	medical records/
28.	((electronic or patient* or school* or ambulance) adj4 (record* or registration* or alert*)).af.
29.	exp patient education/
30.	((patient* or inpatient* or outpatient*) adj3 (inform* or advice or advis* or need* or requirement* or support* or access* or service* or educat* or learn* or teach* or train* or network*)).af.
31.	((("nurse specialist*" or pharmacist* or dentist* or "healthcare professional*" or "health care professional*" or "health professional*" or psychiatrist* or psychologist* or psychotherapist* or counselor* or counsellor*) adj3 (inform* or advice or advis* or need* or requirement* or support* or access* or educat* or learn* or teach* or train*)).af.
32.	or/14-31
33.	13 and 32

## B.2 Health Economics literature search strategy

Health economic evidence was identified by conducting searches using terms for a broad Adrenal Insufficiency population. The following databases were searched: NHS Economic Evaluation Database (NHS EED - this ceased to be updated after 31st March 2015), Health Technology Assessment database (HTA - this ceased to be updated from 31st March 2018) and The International Network of Agencies for Health Technology Assessment (INAHTA). Searches for recent evidence were run on Medline and Embase from 2014 onwards.

**Table 6: Database parameters, filters and limits applied.**

Database	Dates searched	Search filters and limits applied
Medline (OVID)	1 January 2014 – 26 September 2023	Health economics studies  Exclusions (animal studies, letters, comments, editorials, case studies/reports)  English language
Embase (OVID)	1 January 2014 – 26 September 2023	Health economics studies  Exclusions (animal studies, letters, comments, editorials, case studies/reports, conference abstracts)  English language

Database	Dates searched	Search filters and limits applied
NHS Economic Evaluation Database (NHS EED) (Centre for Research and Dissemination - CRD)	Inception –31 <sup>st</sup> March 2015	
Health Technology Assessment Database (HTA) (Centre for Research and Dissemination – CRD)	Inception – 31 <sup>st</sup> March 2018	
The International Network of Agencies for Health Technology Assessment (INAHTA)	Inception - 26 September 2023	English language

### Medline (Ovid) search terms

1.	exp Adrenal Insufficiency/
2.	Adrenal Hyperplasia, Congenital/
3.	(addison* disease or addisonian*).ti,ab,kf.
4.	((adrenal* or adrenocort* or adreno cort*) adj3 (insufficien* or inadequa* or deficien* or suppress* or hypofunction* or disorder* or underactiv* or dysfunction* or abnormal* or problem* or crisis or crises or dysgenesis or destruction or destroy* or hyperplasia or hypoplasia or failure* or fails or failed or fatigue or inhibit* or damage* or disruption*).ti,ab,kf.
5.	((cortisol or aldosterone or adrenocorticotrop* or adreno corticotrop* or ACTH or corticotropi* releas* or corticotropi* releas* or corticoliberin or CRH) adj3 (insufficien* or inadequa* or deficien* or suppress* or reduc* or decreas* or descend* or diminish* or lack* or less or lessen* or low or lower* or limited)).ti,ab,kf.
6.	(hypoadrenal* or hypo adrenal* or hypoadrenocorticism or hypo adrenocorticism or adrenoleukodystrophy or adreno leukodystrophy or adrenomyeloneuropathy or adreno myeloneuropathy or hypoaldosteronism or hypo aldosteronism).ti,ab,kf.
7.	((adrenogenital or adreno genital) adj (syndrome or disorder*).ti,ab,kf.
8.	((haemorrhag* or hemorrhag* or bleed*) adj3 adrenal*).ti,ab,kf.
9.	(Bronze Schilder* Disease or Melanodermic Leukodystrophy or Schilder-Addison* Complex or Siemerling-Creutzfeldt* Disease).ti,ab,kf.
10.	((Allgrove or 3A or TripleA or AAA) adj syndrome).ti,ab,kf.
11.	(CAH or X-ALD).ti,ab.
12.	(Waterhouse-Friderichsen* syndrome or antiphospholipid syndrome).ti,ab,kf.
13.	Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.ti,ab,kf.
14.	or/1-13
15.	letter/
16.	editorial/
17.	news/
18.	exp historical article/
19.	Anecdotes as Topic/
20.	comment/
21.	case reports/
22.	(letter or comment*).ti.
23.	or/15-22
24.	randomized controlled trial/ or random*.ti,ab.

25.	23 not 24
26.	animals/ not humans/
27.	exp Animals, Laboratory/
28.	exp Animal Experimentation/
29.	exp Models, Animal/
30.	exp Rodentia/
31.	(rat or rats or mouse or mice or rodent*).ti.
32.	or/25-31
33.	14 not 32
34.	limit 33 to English language
35.	Economics/
36.	Value of life/
37.	exp "Costs and Cost Analysis"/
38.	exp Economics, Hospital/
39.	exp Economics, Medical/
40.	Economics, Nursing/
41.	Economics, Pharmaceutical/
42.	exp "Fees and Charges"/
43.	exp Budgets/
44.	budget*.ti,ab.
45.	cost*.ti.
46.	(economic* or pharmaco?economic*).ti.
47.	(price* or pricing*).ti,ab.
48.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
49.	(financ* or fee or fees).ti,ab.
50.	(value adj2 (money or monetary)).ti,ab.
51.	or/35-50
52.	34 and 51
53.	limit 52 to yr="2014 -Current"

**Embase (Ovid) search terms**

40.	exp Adrenal cortex insufficiency/
41.	Congenital adrenal hyperplasia/
42.	(addison* disease or addisonian*).ti,ab,kf.
43.	((adrenal* or adrenocort* or adreno cort*) adj3 (insufficien* or inadequa* or deficien* or suppress* or hypofunction* or disorder* or underactiv* or dysfunction* or abnormal* or problem* or crisis or crises or dysgenesis or destruction or destroy* or hyperplasia or hypoplasia or failure* or fails or failed or fatigue or inhibit* or damage* or disruption*)).ti,ab,kf.
44.	((cortisol or aldosterone or adrenocorticotrop* or adreno corticotrop* or ACTH or corticotropi* releas* or corticotrophi* releas* or corticoliberin or CRH) adj3 (insufficien* or inadequa* or deficien* or suppress* or reduc* or decreas* or descend* or diminish* or lack* or less or lessen* or low or lower* or limited)).ti,ab,kf.

45.	(hypoadrenal* or hypo adrenal* or hypoadrenocorticism or hypo adrenocorticism or adrenoleukodystrophy or adreno leukodystrophy or adrenomyeloneuropathy or adreno myeloneuropathy or hypoaldosteronism or hypo aldosteronism).ti,ab,kf.
46.	((adrenogenital or adreno genital) adj (syndrome or disorder*)).ti,ab,kf.
47.	((haemorrhag* or hemorrhag* or bleed*) adj3 adrenal*).ti,ab,kf.
48.	(Bronze Schilder* Disease or Melanodermic Leukodystrophy or Schilder-Addison* Complex or Siemerling-Creutzfeldt* Disease).ti,ab,kf.
49.	((Allgrove or 3A or TripleA or AAA) adj syndrome).ti,ab,kf.
50.	(CAH or X-ALD).ti,ab.
51.	(Waterhouse-Friderichsen* syndrome or antiphospholipid syndrome).ti,ab,kf.
52.	Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.ti,ab,kf.
53.	or/1-13
54.	letter.pt. or letter/
55.	note.pt.
56.	editorial.pt.
57.	case report/ or case study/
58.	(letter or comment*).ti.
59.	(conference abstract* or conference review or conference paper or conference proceeding).db,pt,su.
60.	or/15-20
61.	randomized controlled trial/ or random*.ti,ab.
62.	21 not 22
63.	animal/ not human/
64.	nonhuman/
65.	exp Animal Experiment/
66.	exp Experimental Animal/
67.	animal model/
68.	exp Rodent/
69.	(rat or rats or mouse or mice or rodent*).ti.
70.	or/23-30
71.	14 not 31
72.	limit 32 to English language
73.	health economics/
74.	exp economic evaluation/
75.	exp health care cost/
76.	exp fee/
77.	budget/
78.	funding/
79.	budget*.ti,ab.
80.	cost*.ti.
81.	(economic* or pharmaco?economic*).ti.
82.	(price* or pricing*).ti,ab.
83.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
84.	(financ* or fee or fees).ti,ab.
85.	(value adj2 (money or monetary)).ti,ab.
86.	or/34-46
87.	33 and 47

88.	limit 48 to yr="2014 -Current"
-----	--------------------------------

**NHS EED and HTA (CRD) search terms**


#1.	MeSH DESCRIPTOR Adrenal Insufficiency EXPLODE ALL TREES
#2.	MeSH DESCRIPTOR Adrenal Hyperplasia, Congenital EXPLODE ALL TREES
#3.	(addison* disease or addisonian)
#4.	(adrenal*) AND (insufficien* or inadequa* or deficien* or hypofunction* or disorder* or underactiv* or dysfunction* or abnormal* or problem* or crisis or crises or dysgenesis or destruction or destroy* or hyperplasia or hypoplasia or failure* or fails or failed)
#5.	(cortisol or aldosterone or adrenocortical or adrenocorticotropi* or ACTH or corticotropi* releas* or corticotropi* releas* or corticoliberin or CRH) AND (insufficien* or inadequac* or deficien* or reduc* or decreas* or descend* or diminish* or lack* or less or lessen* or low or lower* or produc* or limited)
#6.	(hypoadrenalism or hypoadrenocorticism or adrenoleukodystrophy or adrenomyeloneuropathy or hypoaldosteronism)
#7.	((Bronze Schilder* Disease or Melanodermic Leukodystrophy or Schilder-Addison* Complex or Siemerling-Creutzfeldt* Disease))
#8.	(Allgrove or 3A or TripleA or AAA) AND (syndrome)
#9.	(X-ALD)
#10.	((Waterhouse-Friderichsen* syndrome or antiphospholipid syndrome))
#11.	((Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy))
#12.	(adrenogenital or adreno genital) AND (syndrome)
#13.	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12

**INAHTA search terms**

1.	((("Adrenal Insufficiency"[mhe]) OR (hypoadrenalism) OR (addison*) OR (adrenal insufficiency) OR (adrenal crisis)))
----	---

## Appendix C Effectiveness evidence study selection

Figure 1: Flow chart of clinical study selection for the review of non-pharmacological management for physiological and psychological stress



## **Appendix D Effectiveness evidence**

No clinical effectiveness evidence was identified.

## **Appendix E Forest plots**


No forest plots included in this review.

## **Appendix F GRADE**

No evidence was identified in this review.



## Appendix G Economic evidence study selection



\* Non-relevant population, intervention, comparison, design or setting; non-English language

## **Appendix H Economic evidence tables**

None.

## **Appendix I Health economic model**

No original economic modelling was undertaken for this review question.

## Appendix J Excluded studies

### J.1 Clinical studies

Table 7: Studies excluded from the clinical review

Study	Reasons for exclusion
<p><a href="#">Burger-Stritt, Stephanie, Eff, Annemarie, Quinkler, Marcus et al. (2020) Standardised patient education in adrenal insufficiency: a prospective multi-centre evaluation.</a> European journal of endocrinology 183(2): 119-127</p>	<p>- Study does not address our clinical question</p>
<p><a href="#">Halpin, K.L.; Paprocki, E.L.; McDonough, R.J. (2019) Utilizing health information technology to improve the recognition and management of life-threatening adrenal crisis in the pediatric emergency department: Medical alert identification in the 21st century.</a> Journal of Pediatric Endocrinology and Metabolism 32(5): 513-518</p>	<p>- Study does not address our clinical question</p>
<p><a href="#">Repping-Wuts, H.J.W.J., Stikkelbroeck, N.M.M.L., Noordzij, A. et al. (2013) A glucocorticoid education group meeting: An effective strategy for improving self-management to prevent adrenal crisis.</a> European Journal of Endocrinology 169(1): 17-22</p>	<p>- Study design not relevant to this review protocol</p>
<p><a href="#">Vidmar, Alaina P, Weber, Jonathan F, Monzavi, Roshanak et al. (2018) Improved medical-alert ID ownership and utilization in youth with congenital adrenal hyperplasia following a parent educational intervention.</a> Journal of pediatric endocrinology &amp; metabolism : JPEM 31(2): 213-219</p>	<p>- Study does not address our clinical question</p>

### J.2 Health Economic studies

None.